In light of the encouraging outcomes observed with KAT6 inhibitors in ER+ breast cancer, it can be inferred that these small‐molecule inhibitors have the potential to deliver new therapeutic strategies for the treatment of ER+/HER2− breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.